-
Leerink Partners Starts Agomab Therapeutics (AGMB) at Outperform
-
Morgan Stanley Starts Agomab Therapeutics (AGMB) at Overweight
-
JPMorgan Starts Agomab Therapeutics (AGMB) at Overweight
-
Agomab (AGMB) files for 12.5M share Nasdaq IPO at $15-$17/sh
-
Agomab (AGMB) files for proposed IPO

